Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. (Q36589374)

15 August 2017

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. (English)

1 reference

15 August 2017

1 reference

24

Bert Vogelstein

0 references

Nicholas J Roberts

Nicholas J Roberts

6

0 references

Victor Velculescu

Victor E Velculescu

23

0 references

Henning Dralle

16

Henning Dralle

1 reference

15 August 2017

25

Kenneth W Kinzler

1 reference

15 August 2017

13

Ralph H Hruban

1 reference

15 August 2017

5

Chetan Bettegowda

1 reference

15 August 2017

12

Laura D Wood

1 reference

15 August 2017

14

Ralph P Tufano

1 reference

15 August 2017

Nickolas Papadopoulos

26

Nickolas Papadopoulos

1 reference

15 August 2017

1

Nishant Agrawal

1 reference

15 August 2017

4

Rebecca Leary

1 reference

15 August 2017

3

Mark Sausen

1 reference

15 August 2017

2

Yuchen Jiao

1 reference

15 August 2017

11

William H Westra

1 reference

15 August 2017

15

Bruce Robinson

1 reference

15 August 2017

Sheetal Bhan

7

1 reference

15 August 2017

Allen S Ho

8

1 reference

15 August 2017

Zubair Khan

9

1 reference

15 August 2017

Justin Bishop

10

1 reference

15 August 2017

Sergio P A Toledo

17

1 reference

15 August 2017

Rodrigo A Toledo

18

1 reference

15 August 2017

Luc G T Morris

19

1 reference

15 August 2017

Ronald A Ghossein

20

1 reference

15 August 2017

James A Fagin

21

1 reference

15 August 2017

Timothy A Chan

22

1 reference

15 August 2017

Barry D Nelkin

27

1 reference

15 August 2017

Douglas W Ball

28

1 reference

15 August 2017

language of work or name

English

0 references

publication date

21 December 2012

1 reference

The Journal of Clinical Endocrinology and Metabolism

15 August 2017

1 reference

15 August 2017

98

1 reference

15 August 2017

2

1 reference

15 August 2017

E364-9

1 reference

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

9 September 2017

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Low-grade serous carcinomas of the ovary contain very few point mutations

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Targeting protein prenylation for cancer therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Frequent pathway mutations of splicing machinery in myelodysplasia

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Mutations in CIC and FUBP1 contribute to human oligodendroglioma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

The cellular response to DNA damage: a focus on MDC1 and its interacting proteins

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

An integrated genomic analysis of human glioblastoma multiforme

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Inhibitors of chronically active ras: potential for treatment of human malignancies.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

New therapeutic approaches to treat medullary thyroid carcinoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

The genomic landscapes of human breast and colorectal cancers

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Medullary thyroid cancer: monitoring and therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

The consensus coding sequences of human breast and colorectal cancers

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Ductal pancreatic cancer in humans and mice.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

BRAF mutation in thyroid cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

9 September 2017

Focus on pancreas cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

The GDNF/RET signaling pathway and human diseases

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3565108

Medullary Thyroid Carcinoma: Who's on First?

4 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23264394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Absence ofTP53 alterations in pheochromocytomas and medullary thyroid carcinomas

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23264394

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1210/JC.2012-2703

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

23264394

1 reference